logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

Quince Therapeutics, Inc.

QNCX

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target anā€¦ read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$23.39

Price

+1.56%

$0.36

$23.03

Previous Close

$23.47

Open

Premium

52w Discount
Market Cap

$6.512m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$33.037m

-0.3%

1y CAGR

-14.0%

3y CAGR

+0.1%

5y CAGR
EPS

-$124.60

+7.6%

1y CAGR

-1.0%

3y CAGR

+11.6%

5y CAGR
Book Value

$15.672m

$26.623m

Assets

$10.951m

Liabilities

$406k

Debt
Debt to Assets

1.5%

-0.3x

Debt to EBITDA
Free Cash Flow

-$39.655m

-21.2%

1y CAGR

-12.4%

3y CAGR

-1.8%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.